We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.
AC Immune Q3 2019 Financial Results and Business Update
November 13, 2019

 CHF 32 Million in Milestone Revenues

Multiple Upcoming Catalysts

Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline

LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today provided a business and clinical update and reported its consolidated financial results for the third quarter of 2019.

Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune, commented: “AC Immune, together with our leading pharmaceutical partners, is advancing one of the industry’s broadest, most diversified development pipelines targeting neurodegenerative diseases. This quarter, we continued to demonstrate strong progress across our pipeline of potentially best-in-class small molecule, antibody, and vaccine therapeutics, as well as our cutting-edge diagnostic agents. This resulted in milestones achieved totaling CHF 32 million which were comprised of CHF 30 million from Eli Lilly and Company and EUR 2 million (CHF 2.2 million) from Life Molecular Imaging.”

Prof. Pfeifer continued, “We anticipate multiple catalysts in 2019 and 2020, highlighted by expected Phase 2 data for semorinemab, our anti-Tau antibody partnered with Genentech/Roche, which we anticipate will be the first Phase 2 data available for a Tau-targeted therapy in Alzheimer’s disease (AD). We also anticipate achieving further progress across our development pipeline with both early and late stage data readouts that we believe will build substantial value for the Company.”

AC Immune’s unique, multi-pronged approach is designed to address the full spectrum of neurodegenerative diseases. By selectively targeting misfolded pathological proteins both intracellularly and extracellularly, and by creating state-of-the-art diagnostic imaging agents that enable early detection of multiple disease pathologies and tracking of disease progression, AC Immune is pioneering a personalized medicine approach to deliver the right therapy to the right patient at the right time.

Research & Development Highlights

  • Earned a EUR 2 million (CHF 2.2 million) milestone following initiation of longitudinal Phase 2 clinical development of next-generation Tau positron emission tomography (PET) tracer PI-2620 by partner Life Molecular Imaging
  • Received first CHF 30 millionmilestone payment from Lilly based on achievement of preclinical milestones related to the oral small molecule Tau Morphomer™ program, which is currently advancing in a Phase 1 clinical study. A second CHF 30 million milestone payment is scheduled for Q1 2020, linked to achievement of further development milestones
  • Vaccinated the first patient in a Phase 1b/2a study of anti-phospho-Tau (anti-pTau) vaccine candidate ACI-35.030 in collaboration with Janssen Pharmaceuticals. ACI-35.030 is intended as a disease-modifying treatment for AD and other Tauopathies
  • Recently hosted a key opinion leader (KOL) event focused on the therapeutic and diagnostic potential of targeting Tau pathology, which highlighted AC Immune’s differentiated Tau pipeline candidates and key  updates  from the ACI-3024 Tau Morphomer™ small molecule  and ACI-35.030 programs
  • Awarded a new grant from The Michael J. Fox Foundation for the Company’s pioneering alpha-synuclein (a-syn) PET tracer program. If successful, AC Immune’s program could deliver the world’s first imaging agent capable of accurately detecting and monitoring progression of Parkinson’s disease

Analysis of Financial Statements for the Three and Nine Months Ended September 30, 2019

  • Cash Position: The Company had a total cash balance of CHF 302.5 million, comprised of CHF 212.5 million in cash and cash equivalents and CHF 90.0 million in short-term financial assets. This compares to a total cash balance of CHF 186.5 million as of December 31, 2018. The increase of CHF 116 million is principally due to the CHF 80 million upfront payment, USD 50 million convertible equity note, and CHF 30 million milestone payment related to the agreement with Lilly. The total shareholders’ equity position increased from December 31, 2018 to CHF 292.4 million from CHF 177.6 million. Further details are available in our corresponding Financial Statements filed on the accompanying Form 6-K
  • Revenues: Revenues for the three and nine months ended September 30, 2019 totaled CHF 33.4 million and CHF 110 million, respectively. This represents an increase of CHF 31.1 million and CHF 104.2 million compared to the respective periods in 2018. The increase for the three-month period relates to the recognition of CHF 30.0 million for the first installment of the first milestone achieved with Lilly and EUR 2 million (CHF 2.2 million) in connection with the initiation of a Phase 2 Trial of Tau PET Tracer with Life Molecular Imaging. The increase for the nine-month period is driven by the recognition of CHF 74.6 million from the right-of-use license and research and development activities linked to the 2018 Lilly agreement and a CHF 30 million payment for the first installment of the first milestone achieved with Lilly
  • R&D Expenditures: R&D expenditures decreased by CHF 0.1 million (-0.6%) and increased CHF 3.6 million (+11%) for the three and nine months ended September 30, 2019 compared to the comparable periods in 2018, respectively. The increase in R&D expenditures in 2019 was largely due to increased investments in non-AD and new discovery programs. For non-AD, the Company increased investment in its Morphomer™ alpha-synuclein programs and continued to advance the clinical development of its anti-Abeta vaccine ACI-24 in Down Syndrome (DS). In new discovery, the Company continued to focus on its neuroinflammation discovery programs while also increasing investment in its anti-a-synuclein antibody. For AD, the Company’s expenditures for the anti-pTau vaccine program decreased due to the completion of certain toxicology and manufacturing work in the prior year as well as a decrease for ACI-24 related to higher costs for the initiation of the Phase 2 study in the prior period
  • G&A Expenses: For the three and nine months ended September 30, 2019, G&A increased CHF 1.0 million (+35%) and CHF 2.1 million (+24%) to CHF 4.0 million and CHF 10.8 million, respectively. Increases are driven by rental, personnel and IT expenses
  • IFRS Income/(Loss) for the period: The Company recorded net income after taxes of CHF 18.2 million and CHF 64.9 million for the three and nine months ended September 30, 2019, respectively, compared with net losses of CHF 13.5 million and CHF 36.3 million for the comparable periods in 2018

About AC Immune
AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen Pharmaceuticals Inc.

As a strategic leader in the field of neurodegenerative diseases, AC Immune has developed a five-point Roadmap to Successful Therapies for Neurodegenerative Diseases that recognizes the importance of treating earlier, targeting Tau, focusing on more homogeneous patient populations, precision medicine and exploring neuroinflammation as a target.

For further information, please contact:

U.S. Investors U.S. Media
Joshua Drumm, Ph.D. Katie Gallagher 
AC Immune Investor Relations LaVoieHealthScience
Phone: +1 646 876 5538 Phone: +1 617 792 3937
E-mail: joshua.drumm@acimmune.com E-mail: kgallagher@lavoiehealthscience.com 
Head of Global Communication European Investors 
Judith Moore Chris Maggos
AC Immune LifeSci Advisors
Phone: +41 79 826 63 82 Phone: +41 79 367 6254 
Email: judith.moore@acimmune.com E-mail: chris@lifesciadvisors.com

Forward-looking statements  
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information—Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Balance Sheets

  As of
September 30,
  As of
December 31,

in CHF thousands        
Non-current assets        
Property, plant and equipment 3,702   3,324  
Right-of-use assets 1,893   -  
Long-term financial assets 304   304  
Total non-current assets 5,899   3,628  
Current assets        
Prepaid expenses 2,997   2,364  
Accrued income 939   3,667  
Finance receivable 100   199  
Other current receivables 2,957   236  
Short-term financial assets 90,000   30,000  
Cash and cash equivalents 212,457   156,462  
Total current assets 309,450   192,928  
Total assets 315,349   196,556  
Shareholders’ equity        
Share capital 1,436   1,351  
Share premium 346,479   298,149  
Accumulated losses (55,532)   (121,877)  
Total shareholders’ equity 292,383   177,623  
Non-current liabilities        
Long-term financing obligation 297   186  
Long-term lease liabilities 1,467   -  
Long-term deferred income 1,092   -  
Net employee defined benefit liabilities 6,098   5,665  
Total non-current liabilities 8,954   5,851  
Current liabilities        
Trade and other payables -   1,979  
Accrued expenses 8,551   10,420  
Short-term deferred income 4,701   351  
Short-term debt obligation 334   332  
Short-term lease liabilities 426   -  
Total current liabilities 14,012   13,082  
Total liabilities 22,966   18,933  
Total shareholders’ equity and liabilities 315,349   196,556  

Statements of Income/(Loss)

  For the Three Months
Ended September 30,
  For the Nine Months
Ended September 30,
  2019   2018   2019   2018  
  (in CHF thousands except for per share data)
Contract revenue 33,411   2,305   109,964   5,791  
Total revenue. 33,411   2,305   109,964   5,791  
Operating expenses                
Research & development expenses (11,478)   (11,546)   (35,770)   (32,150)  
General & administrative expenses (3,956)   (2,930)   (10,835)   (8,703)  
Total operating expenses (15,434)   (14,476)   (46,605)   (40,853)  
Operating income/(loss) 17,977   (12,171)   63,359   (35,062)  
Finance income / (expense), net 249   (1,314)   (1,564)   (1,149)  
Change in fair value of conversion feature     4,542    
Interest income 73     237   3  
Interest expense (86)   (31)   (1,686)   (66)  
Finance result, net 236   (1,345)   1,529   (1,212)  
Income/(loss) before tax 18,213   (13,516)   64,888   (36,274)  
Income tax expense        
Income/(loss) for the period 18,213   (13,516)   64,888   (36,274)  
Income/(loss) per share (EPS):                
Basic income/(loss) for the period attributable to equity holders 0.25   (0.21)   0.92   (0.61)  
Diluted income/(loss) for the period attributable to equity holders 0.25   (0.21)   0.92   (0.61)  

Statements of Comprehensive Income/(Loss)

  For the Three Months
Ended September 30,
  For the Nine Months
Ended September 30,
  2019   2018   2019   2018  
  (in CHF thousands)
Income/(loss) for the period 18,213   (13,516)   64,888   (36,274)  
Other comprehensive income/(loss) not to be reclassified to income or loss in subsequent periods (net of tax):                
Re-measurement losses on defined benefit plans        
Total comprehensive income/(loss), net of tax 18,213   (13,516)   64,888   (36,274)  

Reconciliation of Income/(Loss) to Adjusted Income/(Loss) and
Earnings/(Loss) Per Share to Adjusted Earnings/(Loss) Per Share

  For the Three Months
Ended September 30,
  For the Nine Months
Ended September 30,
  2019   2018   2019   2018  
  (in CHF thousands except for share and per share data)
Income/(Loss) 18,213   (13,516)   64,888   (36,274)  
Non-cash share-based payments (a) 882   583   2,027   1,897  
Foreign currency (gains)/losses (b) (272)   1,296   286   1,101  
Effective interest expense (c)     1,355    
Change in fair value of conversion feature (d)     (4,542)    
Adjusted Income/(Loss) 18,823   (11,637)   64,014   (33,276)  
Earnings/(Loss) per share – basic 0.25   (0.21)   0.92   (0.61)  
Earnings/(Loss) per share – diluted 0.25   (0.21)   0.92   (0.61)  
Adjustment to earnings/(loss) per share – basic 0.01   0.03   (0.02)   0.05  
Adjustment to earnings/(loss) per share – diluted 0.01   0.03   (0.01)   0.05  
Adjusted earnings/(loss) per share – basic 0.26   (0.18)   0.91   (0.56)  
Adjusted earnings/(loss) per share – diluted 0.26   (0.18)   0.91   (0.56)  
Weighted-average number of shares used to compute Adjusted earnings/(loss) per share – basic 71,822,884   64,862,822   70,184,257   59,912,283  
Weighted-average number of shares used to compute Adjusted earnings/(loss) per share – diluted. 72,281,264   64,862,822   70,700,690   59,912,283  

(a)  Reflects non-cash expenses associated with share-based compensation for equity awards issued to Directors, Management and employees of the Company. This expense reflects the awards’ fair value recognized for the portion of the equity award which is vesting over the period.

(b)  Reflects foreign currency remeasurement gains and losses for the period, predominantly impacted by the change in the exchange rate between the US Dollar and the Swiss Franc.

(c)  Effective interest expense for the period relates to the accretion of the Company’s convertible loan in accordance with the effective interest method.

(d)  Change in fair value of conversion feature that is bifurcated from the convertible loan host debt with Lilly.

For the three and nine months ended September 30, 2019, adjustments increased net income and decreased net income by CHF 0.6 million and CHF 0.9 million compared with decreases to the net losses by CHF 1.9 million and CHF 3.0 million for the comparable periods in 2018, respectively. The Company recorded CHF 0.9 million and CHF 2.0 million for the three and nine months, respectively, for share-based compensation expenses. There were foreign currency remeasurement gains of CHF 0.3 million and remeasurement losses of CHF 0.3 million, respectively, related to foreign currency fluctuations. The Company recorded nil and CHF 1.4 million for amortization of effective interest for the three and nine months ended September 30, 2019, respectively. Finally, the Company recognized nil and a CHF 4.5 million gain for the change in fair value of the liability related to the conversion feature.


Source: AC Immune SA